The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'October, 2018'. If you still can't find what you are looking for, try using the search box.
AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line. PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy
Read the rest of entry »
Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.
The OBN Annual Awards celebrates the achievements of the UK life sciences industry.
HistologiX Ltd, a leading GLP/GCP compliant IHC and Histology lab, has been acquired by The Intelligent Tissue Group Ltd, joining Tissue Solutions Ltd, world leaders in human tissue provision, to provide a comprehensive integrated range of tissue related CRO services.
ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service. Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.
SynbiCITE, the UK’s national centre for commercialisation of synthetic biology, is pleased to announce the launch of a new five-year strategy underpinned by a new £5M grant from UKRI and other sources. The new strategy will see the launch of SynbiCITE 2.0, which aims to expand and develop SynbiCITE’s reach within the UK’s synthetic biology innovation and academic ecosystem, and create a single highly interconnected UK innovation cluster.
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK. The grant will enable the Company to buy equipment and move forward with its plans to extend its pilot scale manufacture of patches formulated with its unique TEPI Patch® technology to GMP manufacture for clinical trials.
Isansys Lifecare's Patient Status Engine wireless patient monitoiring platform could help deliver millions of pounds worth of savings to the NHS.
Science World, the Fisher Scientific Laboratory Experience, made its successful return to Emirates Old Trafford – Lancashire County Cricket Club, Manchester on 27 September. The event, hosted by Thermo Fisher Scientific, showcased the latest in laboratory innovations available through Fisher Scientific.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.